Eli Lilly Retatrutide Q1 2027 BLA Filing Plan Follow-Through After TRIUMPH-2 and TRIUMPH-3 Wins; Early-Access Program Rolls Out for Defined Patient Groups
Eli Lilly (NYSE: LLY) continued rollout through September 2026 of the early-access program for retatrutide (a once-weekly subcutaneous injectable GIP/GLP-1/glucagon triple agonist peptide for obesity) ahead of the Q1 2027 BLA submission plan confirmed after the July 23, 2026 TRIUMPH-2 and TRIUMPH-3 Phase 3 wins in obesity plus type 2 diabetes and obesity plus established cardiovascular disease. The 12 mg retatrutide dose produced 28.3% mean weight loss at 80 weeks in the TRIUMPH-1 Phase 3 obesity monotherapy trial reported in May 2026, the highest weight loss reported for any obesity therapy in a Phase 3 setting. TRIUMPH-4 (knee osteoarthritis, 68 weeks) added 28.7% weight loss plus improvements in pain and physical function. Seven Phase 3 readouts total are expected across the retatrutide program in 2026. Lilly management has framed retatrutide as the successor commercial franchise to Zepbound and Mounjaro, with launch anticipated 2027-2028 under the Most Favored Nation pricing framework that would apply from initial approval per the November 2025 pricing agreement.